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The introduction of anti-CD20 monoclonal antibodies such as ritux-imab, ofatumumab, or obinutuzumab improved the therapy of B-cell malignancies even though the precise physiological role and
regulation of CD20 remains unclear. Furthermore, CD20 expression is
highly variable between different B-cell malignancies, patients with the
same malignancy, and even between intraclonal subpopulations in an
individual patient. Several epigenetic (EZH2, HDAC1/2, HDAC1/4,
HDAC6, complex Sin3A-HDAC1) and transcription factors (USF,
OCT1/2, PU.1, PiP, ELK1, ETS1, SP1, NFκB, FOXO1, CREM, SMAD2/3)
regulating CD20 expression (encoded by MS4A1) have been character-
ized. CD20 is induced in the context of microenvironmental interactions
by CXCR4/SDF1 (CXCL12) chemokine signaling and the molecular func-
tion of CD20 has been linked to the signaling propensity of B-cell receptor
(BCR). CD20 has also been shown to interact with multiple other surface
proteins on B cells (such as CD40, MHCII, CD53, CD81, CD82, and CBP).
Current efforts to combine anti-CD20 monoclonal antibodies with BCR
signaling inhibitors targeting BTK or PI3K (ibrutinib, acalabrutinib, idelal-
isib, duvelisib) or BH3-mimetics (venetoclax) lead to the necessity to bet-
ter understand both the mechanisms of regulation and the biological func-
tions of CD20. This is underscored by the observation that CD20 is
decreased in response to the “BCR inhibitor” ibrutinib which largely pre-
vents its successful combination with rituximab. Several small molecules
(such as histone deacetylase inhibitors, DNA methyl-transferase
inhibitors, aurora kinase A/B inhibitors, farnesyltransferase inhibitors,
FOXO1 inhibitors, and bryostatin-1) are being tested to upregulate cell-
surface CD20 levels and increase the efficacy of anti-CD20 monoclonal
antibodies. Herein, we review the current understanding of CD20 func-
tion, and the mechanisms of its regulation in normal and malignant B
cells, highlighting the therapeutic implications.
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ABSTRACT
Introduction
The approval of the anti-CD20 antibody rituximab by the Food and Drug
Administration in 1997 was a conceptual breakthrough in the treatment of B-cell
malignancies. Rituximab improved progression-free survival and overall survival
rates when added to chemotherapy in “mature” B-cell leukemias and lymphomas
such as chronic lymphocytic leukemia (CLL), follicular lymphoma, and diffuse
large B-cell lymphoma (DLBCL), and this proved that monoclonal antibodies could
be used in cancer treatment.1 Additionally, rituximab maintenance therapy has
been introduced for some of these diseases. Based on the success of rituximab, new
engineered anti-CD20 monoclonal antibodies, namely ofatumumab and obinu-
tuzumab, were developed. Preclinical studies suggest that these new anti-CD20
monoclonal antibodies are superior to rituximab for some mechanisms of action.2
Anti-CD20 monoclonal antibodies might act through several mechanisms (Figure
1) including complement-dependent cytotoxicity (CDC), complement-dependent
cellular cytotoxicity, antibody-dependent cellular cytotoxicity (ADCC), antibody-
dependent cellular phagocytosis, and direct apoptosis
induction, as has been elegantly reviewed by others.3,4 All
these mechanisms were observed in vitro and/or in animal
models, and likely act in vivo in patients as well, but their
relative contribution to the clinical effects of the different
anti-CD20 monoclonal antibodies is still debated. It is also
unclear why the application of novel engineered mono-
clonal antibodies provides clinical benefit in comparison
to rituximab in some B-cell malignancies, but not in oth-
ers. For example in CLL patients, obinutuzumab is superi-
or to rituximab when combined with chlorambucil, as
judged by the number of complete remissions and pro-
longed progression-free survival.5 A much less significant
improvement in progression-free survival has also been
demonstrated in previously untreated follicular lym-
phoma patients treated with obinutuzumab-based
chemoimmunotherapy compared to rituximab-based
chemoimmunotherapy.6,7 Finally, a phase III clinical study
demonstrated no improvement in progression-free sur-
vival in a large cohort of treatment-naïve DLBCL patients
when comparing obinutuzumab plus CHOP (cyclophos-
phamide, adriamycin, vincristine and prednisone) versus
rituximab plus CHOP.8 It is important to note that in these
trials, obinutuzumab was used at doses and schedules
quite different from those of rituximab. For example, in
the CLL trial5 a flat obinutuzumab dose of 1000
mg/patient was used (on days 1, 8, and 15 of cycle 1 and
on day 1 of cycles 2-6), while rituximab was used at a dose
of 375 mg/m2 on day 1 of cycle 1 and 500 mg/m2 on day 1
of cycles 2-6. Overall, in this CLL trial the median cumu-
lative rituximab dose per patient was 64% of the obinu-
tuzumab dose (these two monoclonal antibodies have a
nearly identical molecular weight).
Currently, efforts have shifted from adding anti-CD20
monoclonal antibodies to chemotherapy to combining
them with novel drugs, such as B-cell receptor (BCR) sig-
naling inhibitors (ibrutinib, idelalisib, etc.)9 or BH3-mimet-
ics inhibiting BCL2 (venetoclax),10 and also the develop-
ment of CD20 targeting chimeric antigen receptor T
cells.11 It is essential to understand the mechanism of
CD20 regulation and function thoroughly and to elucidate
the mechanism of action of monoclonal antibodies in
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Figure 1. Summary of the known mechanisms of action of anti-CD20 monoclonal antibodies and an overview of potential factors affecting resistance to anti-CD20
therapy in malignant B cells. Anti-CD20 monoclonal antibodies act through several mechanisms, including complement-dependent cytotoxicity (CDC), complement-
dependent cellular cytotoxicity (CDCC), antibody-dependent cellular phagocytosis (ADCP), antibody-dependent cellular cytotoxicity (ADCC), and induction of direct
apoptosis. 
order to fully exploit their therapeutic potential. This is
underscored by the recent disappointing results of clinical
trials testing rituximab’s addition to the BTK inhibitor
ibrutinib in CLL, which showed practically no benefit of
such a combination.12 Here we summarize the research
describing the regulation and function of CD20 in normal
and malignant B cells, and the therapeutic implications of
these observations, including the relevance for the combi-
nation of “BCR inhibitors” with anti-CD20 monoclonal
antibodies.
CD20 gene and protein structure
CD20 is a 33-37 kDa non-glycosylated protein
expressed on the surface of normal and malignant B lym-
phocytes, and belongs to the MS4A (membrane-spanning
4-domain family A) protein family.13 To date, 18 MS4A
family members have been identified, besides MS4A1
(encoding CD20), also the high-affinity immunoglobulin E
receptor β subunit (MS4A2/FceRIβ) or HtM4 gene
(MS4A3) (reviewed by Eon Kuek14). MS4A proteins are
transmembrane molecules and they are predicted to share
a similar polypeptide sequence and overall topological
structure. The majority of MS4A genes, including MS4A1,
are localized within a cluster on chromosome 11q12 in
humans (chromosome 19 in mice), and two members
from a closely related TMEM176 gene family were identi-
fied in chromosome region 7q36.1.14
The MS4A1 gene is 16 kb long, comprises eight exons,
and several different CD20 mRNA transcripts have been
annotated.13 The dominant CD20 mRNA variant is 2.8 kb
long and uses all eight exons, whereas the second most
common form is 263 bases shorter, as it skips exon II. A
minor 3.5 kb mRNA results from splicing exons in the
upstream region into an internal 3' splice site located in
exon I. However, all three transcripts are translated into
identical full-length CD20 protein as the translation start
codon is localized within exon III. Moreover, other alter-
native transcripts were identified in malignant B cells,
some of them encoding truncated forms of CD20 protein
leading to impaired binding of anti-CD20 monoclonal
antibodies.15,16
CD20 protein consists of four hydrophobic transmem-
brane domains, one intracellular and two extracellular
domains (large and small loops) with both N- and C- ter-
mini residing within the cytosol.14 Three CD20 isoforms
(33, 35 and 37 kDa) resulting from different phosphoryla-
tion have been identified, and CD20 phosphorylation was
reported to be higher in proliferating malignant B cells
than in resting B cells.17 Normally, CD20 does not form
hetero-oligomers,18 but exists on the cell surface as homo-
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Figure 2. A schematic view of interacting partners of CD20 on cell membrane and mechanisms of CD20 gene (MS4A1) regulation in malignant B cells. mAbs: mon-
oclonal antibodies; BCR: B-cell receptor; HDACi: histone deacetylase inhibitors; DNMTi: DNA methyl-transferase inhibitors; NICD: NOTCH1 intracellular domain; TGFβ:
transforming growth factor β. 
dimeric and homo-tetrameric oligomers associated with
other cell-surface and cytoplasmic proteins contributing to
the signal transduction.17,19,20 Tetraspanin proteins tend to
associate with multiple other proteins in membrane
microdomains (Figure 2).21 Energy transfer experiments
indicate that CD20 is in close proximity to other tetraspan
molecules, such as CD53, CD81, and CD82, forming
supramolecular complexes (Figure 2).22 CD20 is also
known to be physically coupled to major histocompatibil-
ity complex class II (MHCII), CD40 molecule, BCR, and
the C-terminal src kinase-binding protein (CBP) that inter-
acts with Src kinases such as LYN, FYN, and LCK (Figure
2).20,23,24 Besides the transmembrane form of CD20, circu-
lating CD20 was reported in CLL patients’ plasma;25 how-
ever, this is likely to be part of a larger protein complex or
a cell membrane fragment originating from cell break-
down.
CD20 is a general B-cell marker expressed by the major-
ity of B cells starting from late pre-B lymphocytes (it is not
expressed by pro-B lymphocytes), and its expression is
lost in terminally differentiated plasmablasts and plasma
cells. Recently, a subset of CD20+ T cells with immune-
regulatory and pro-inflammatory activity has been
described; however, the clinical relevance of this remains
to be determined.26 In B-cell malignancies, the level of
CD20 expression is extremely variable depending on the
specific neoplasm, with the lowest CD20 expression usu-
ally being observed in patients with CLL and the highest
CD20 cell-surface expression on DLBCL and hairy cell
leukemia cells.27,28 Within CLL, it was noted that CD20
expression was also relatively higher in a disease subtype
with a mutated variable region of immunoglobulin gene
(IGHV) than in the subtype with unmutated IGHV.29 Some
studies described that higher CD20 expression levels cor-
relate with longer overall survival in patients with B-cell
lymphomas treated with rituximab,30,31 although this
remains controversial.32,33 Notably, CD20 levels are hetero-
geneous not only among patients with the same malig-
nancy, but also within the intraclonal cell subpopulations
in an individual patient.34
CD20 function: a link to B-cell receptor signaling 
and microenvironmental interactions 
The biological function of CD20 in B cells and its phys-
iological ligand, if any, remain unclear. Some light on
CD20 function has been shed by a case report of a patient
with a common variable immunodeficiency and CD20
loss caused by a homozygous mutation in an exon 5
splicing site of MS4A1. The mutation led to alternative
splicing with complete deletion of exon 5 and insertion of
intron sequences and thus a truncated form of MS4A1
mRNA.35 Due to this homozygous mutation, the patient
completely lacked cell-surface CD20. This did not disturb
precursor B-cell differentiation in the bone marrow, as the
patient had normal serum IgM levels and normal B-cell
numbers. However, CD20 deficiency resulted in a
reduced number of circulating memory B cells, reduced
isotype switching of Ig, and decreased IgG antibody lev-
els. In agreement with this observation, challenging the
patient’s primary B cells in vitro using T-dependent and T-
independent antigens led to the normal proliferation and
secretion of IgM but reduced production of IgG. Given
these data it is surprising that after repeated vaccinations
the patient displayed a reduced ability to respond to T-
independent antigens (pneumococcal polysaccharide vac-
cine), but a normal reaction to T-dependent antigens
(anti-tetanus toxoid IgG). 
Cases of a homozygous mutation in the MS4A1 gene in
humans are extremely rare, which prompted the genera-
tion of mouse models. This is a reasonable approach,
since human and mice CD20 proteins share most struc-
tural features and a conserved amino acid sequence
(~75% homology) with only a few structural modifica-
tions in the transmembrane and N- and C-terminal cyto-
plasmic domains.36 CD20 in both humans and mice is B-
cell specific, being first expressed by late pre-B cells in the
bone marrow, predominantly after Ig heavy chain
rearrangement. Uchida et al. created a mouse model with
a homozygous mutation in the MS4A1 gene.36 These
CD20-less mice had normal B-cell differentiation, isotype
switching, maturation, mitogen-induced proliferation,
and tissue localization. Similarly, CD20 deletion was not
observed to have any effect on proliferation and differen-
tiation in mice with MS4A1 disruption, generated by
Neuberger’s group.37 CD20-/- mice immunized with T-
dependent antigens showed impaired humoral immunity
and primary and secondary immune responses connected
with reduced numbers of germinal center B cells.38
Altogether, these studies in human and murine CD20-
deficient B cells suggest that CD20 is required for both
optimal T-independent humoral immunity, and also for a
response to T-dependent antigens. However, it should be
taken into consideration that the T-dependent immune
response might be impaired due to the loss of CD20 in a
small CD20+ population of T cells whose specific role in
the immune system remains unclear.26 Overall, the rela-
tively mild phenotype resulting from CD20 loss in
humans and mice is somewhat surprising since CD20
was reported to be physically and functionally coupled to
MHCII and CD40 (Figure 2),23 which are both critical for
B- and T-cell interactions. 
The development of humoral immunity requires a
functional BCR signaling pathway, and CD20 was report-
ed to be co-localized in lipid rafts39 and to interact directly
physically with BCR.20 Additionally, it has been observed
that CD20 becomes heavily phosphorylated after mito-
gen stimulation, and it has been proposed that it might
function as a calcium channel and be involved in B-cell
activation.17,19 This is in line with in vitro data showing that
BCR-activated calcium flux was reduced after siRNA-
mediated CD20 down-modulation in human B-cell
lines.34,40 Moreover, direct CD20 crosslinking induces
acute signaling similar to BCR crosslinking, including cal-
cium flux, and overlapping transcription patterns in
human lymphoma cell lines.41,42 Kheirallah et al. also
demonstrated that pretreatment of lymphoma cell lines
with rituximab interferes with BCR signaling cascade
stimulation, suggesting that both cell-surface proteins
might share the same signaling pathway components and
activate negative feedback regulatory mechanisms,
including BCR downmodulation.43 We and others have
shown that levels of cell-surface CD20 on primary CLL
cells are correlated (and possibly co-regulated) with cell-
surface BCR expression.34 Additionally, we observed in
vivo that CLL cells that have recently exited the lymph
node microenvironment to the peripheral blood are char-
acterized by a marked upregulation of CD20 levels.44 This
stems from the activation of CXCR4 by SDF1
chemokine, which leads to transcriptional activation of
CD20 expression. Moreover, CD20 cell-surface levels are
CD20: functions and regulation
haematologica | 2020; 105(6) 1497
induced in CLL cells treated by microenvironmental fac-
tors such as IL4, TNFα, INFα or GMCSF in vitro45-47(and
our unpublished data). 
CD20 silencing in malignant B cells revealed that CD20
affects the phosphorylation of multiple BCR-associated
kinases and proteins after BCR-ligation (LYN, SYK, GAB1,
and ERK).34 This suggests that both CD20 and BCR are
induced in immune niches34 to allow effective and strong
BCR activation by an antigen or CD20 might also be
involved in some form of “tonic” BCR signaling.48 This has
important implications for combining BCR inhibitors with
antibodies targeting CD20. We have shown that inhibit-
ing BTK interferes with CXCR4 signaling in CLL cells and
thus leads to very significant repression of CD20 expres-
sion in CLL cells. This might partially explain the lack of
clinical benefit from adding rituximab to ibrutinib.12
Ibrutinib was recently tested and approved in combina-
tion with a more potent anti-CD20 monoclonal antibody,
namely obinutuzumab,49 whose efficacy is less affected by
lower levels of CD20 on the cell-surface. We also suggest
that PI3K inhibition, like BTK inhibition, might lead to the
downmodulation of CD20, but this remains to be formal-
ly proven, and the implications for the therapeutic combi-
nation of rituximab with PI3K inhibitors (including idelal-
isib) or other BTK inhibitors (such as acalabrutinib) are
unclear. 
Altogether, functional studies suggest that CD20 is
physiologically directly required for efficient BCR signal-
ing in B cells. This is also in line with some data from the
CD20 mouse models. In Uchida’s CD20-/- mice model,
cell-surface IgM expression on both mature and immature
B cells was 20 – 30% lower than that on B cells from wild-
type littermates, which was connected with reduced BCR-
and CD19-dependent intracellular calcium mobilization.36
In a study by Morsy et al., the reduction in BCR-associated
calcium mobilization in CD20-/- murine B cells was pro-
posed to  be caused by a defect in calcium transport rather
than in its release from intracellular stores.38 In our opin-
ion, there is a sufficient body of evidence suggesting that
CD20 is involved in BCR signaling, but it is unclear
whether this is related to its putative function as a calcium
channel and/or other function(s). Similarly, it is not clear if
other molecular pathways or B-T-cell interactions might
be affected by CD20 levels on the cell-surface of B cells. 
Regulation of CD20 transcription and its "therapeutic
modulation" 
Rituximab is one of the most effective and widely used
therapeutic monoclonal antibodies, but malignant B cells
can become relatively resistant to such therapy.
Mechanisms of malignant B cells’ resistance to anti-CD20
monoclonal antibodies include insufficient CDC activity
due to increased expression of regulatory proteins CD55,
CD59 or factor H,50,51 less effective ADCC in cases with
specific FcgRIII polymorphism,52 exhaustion of cytotoxic
mechanisms (such as complement/effector cells),53,54 poly-
morphism in the complement component C1qA,55 or
abnormal composition and localization of lipid rafts and
thus impaired rituximab-induced apoptosis (Figure 1).56
Nevertheless, one of the most straightforward and fre-
quent causes of resistance to anti-CD20 monoclonal anti-
bodies is reduced CD20 expression, which can be due to
(de)regulation of transcriptional, post-transcriptional, or
post-translational mechanisms (including CD20 protein
transport to the cell surface57).
Regarding transcriptional regulation, the MS4A1 gene
lacks several regulatory elements typical of other B-cell
specific genes, including TATA and CAAT box. The
G. Pavlasova and M. Mraz
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Figure 3. A schematic of the proximal region of MS4A1 promoter with transcription factor binding sites. Several regulatory elements differ in nucleotide sequence
when comparing data from literature and the TRANSFAC database. Shimizu et al.65 described the GC-box binding SP1 as being located in a region between bases -
548 and -539, but the TRANSFAC database identified a GC-box in a position -234 to -224 bp [based on the SP1 chromatin immunoprecipitation sequencing data
(ENCODE ID: ENCSR000BHK)]. A BAT-box was identified by Thévenin et al.58 in the proximal promoter region located between bases -214 and -202 (in bold), while
others describe it between bases -214 and -200.59,65 The PU.1/PiP binding site was originally defined as a sequence between -161 and -148 bp,59 but TRANSFAC pre-
dicts it in the region from -120 to -107 bp (in italics). The E-box sequence is usually described as the CACCTG sequence between -44 and -39 bp (in bold)59,62,65 but
the TRANSFAC database suggests (based on ENCODE ID: ENCSR000BGI) a longer sequence from -48 to -35 bp (in italics). FOXO1 was suggested as being recruited
to the MS4A1 promoter indirectly by the DNA-binding element between bases -182 and -88.70 NFκB binds into the region of the MS4A1 promoter between -425 and
-417 bp.62
Table 1. Positive and negative regulators of MS4A1 (CD20 gene) tran-
scription.
           Positive regulatorsRef         Negative regulatorsRef
Transcription factors                           
               USF, TFE359                              FOXO170
               OCT1,58 OCT258                        CREM69
               PU.1/PiP (IRF4)59                    SMAD2/399
               ELK1,64 ETS164                         MYC67
               SP165                                          
               NFκB65
               CHD4,69* MBD269*
Epigenetic regulators                          
               Unknown                                 Sin3A-HDAC176
                                                                  EZH280
                                                                  HDAC1/481
                                                                  HDAC682
                                                                  RBPJ and mutated NICD of NOTCH195
* The DNA binding site in the MS4A1 promoter has not been defined. NICD: NOTCH1
intracellular domain.
CD20: functions and regulation
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known positive regulatory elements present in the
MS4A1 promoter include an E-box motif (binding mE3-
specific transcription factors such as USF and TFE3),
“PU.1/PiP” binding site and a BAT box (Figure 3, Table
1).58,59 The BAT box is a sequence element present in the
most proximal region and serves as a binding site for the
transcription factors OCT1 and OCT2 with a B-cell
restricted co-activator BOB (Figure 3, Table 1).58,60 The
BAT element is important for the high constitutive
expression of CD20 in mature B cells and the induction of
CD20 in pre-B cells.58 The “PU.1/PiP” binding site is a
putative site for transcription factors belonging to the ETS
family (e.g. PU.1) and protein PiP (IRF4) (Figure 3, Table
1). PiP is recruited to this DNA binding site indirectly by
phosphorylated PU.159 and a “PU.1/PiP” binding site
seems to be critical for CD20 expression as it is occupied
only in CD20-positive B cells. Additionally, PU.1/Pip are
downregulated during plasma cell differentiation,61 and
mutations in this binding site nearly completely abol-
ished the promoter activity of MS4A1.59 Moreover, tran-
scriptional CD20 activation in primary CLL and non-
Hodgkin lymphoma (NHL) B cells was associated with
increased PU.1 and OCT2 binding to the MS4A1 promot-
er in response to farnesyltransferase inhibition.62
Downregulating PU.1 expression by overexpression of its
negative regulator, namely FLT3, also led to lower CD20
expression in CLL cells and vice versa.63
Several transcription factors from the ETS family, such
as ELK1 and ETS1, were observed to be activated in an
ERK-dependent manner and enhance CD20 cell-surface
expression in B-NHL cell lines and primary CLL cells after
bryostatin-1 treatment in vitro (which activates the
MEK1/ERK-1/2 pathway via PKC) (Figure 2, Table 1).64
Furthermore, it was proposed that NFκB might positively
regulate CD20 expression62,65 and gemcitabine treatment
of DLBCL cell lines augmented CD20 expression together
with NFκB signaling activation (Figures 2 and 3, Table 1).66
Chromatin immunoprecipitation sequencing analysis
also revealed MS4A1 as a direct MYC target gene in
Burkitt lymphoma cell lines (Table 1), and MYC silencing
resulted in CD20 upregulation.67 The repression of CD20
by MYC is surprising and remains to be confirmed in
other lymphoma cell types, since B-cell activation (also
leading to MYC expression) is generally known to induce
CD20 expression in B cells.68 To reveal other factors regu-
lating CD20 expression, Slabicki et al.69 performed a
genome-wide RNA interference screening using a library
of small hairpin RNAs delivered into Raji cells (Burkitt
lymphoma cell line) by lentiviral vectors. They identified
37 potential CD20 repressors and 51 activators, among
them CHD4 and MBD2 as novel MS4A1 inducers (Table
1). Both CHD4 and MBD2 are members of the nucleo-
some remodeling deacetylase complex, which plays an
important role in the regulation of gene transcription.
This screening also revealed CREM as the top candidate
for CD20 repression, and the presence of three half-
cAMP response elements in MS4A1 promoter sites
(TGACG) led to the notion that cAMP-mediated signal
transduction plays a role in CD20 transcriptional repres-
sion. Most recently, FOXO1 transcription factor was
described as a negative MS4A1 transcription regulator in
lymphoma B cells (Figures 2 and 3, Table 1).70 This is in
agreement with the observation that DLBCL patients
with activating FOXO1 mutations have shorter overall
survival upon rituximab-based therapy.71 As the exact
localization of the putative FOXO1 binding site in the
MS4A1 promoter was not determined, it is believed that
FOXO1 binds indirectly to the DNA-binding element
between -182 and -88 bp (Figure 3).70 These data (and our
unpublished data) suggest that FOXO1 inhibitors might
theoretically be combined with anti-CD20 antibodies to
induce CD20 expression and potentiate the effect of the
monoclonal antibodies. Similarly, other groups have pro-
posed that inhibiting aurora kinase A/B could also lead to
upregulation of CD20 and potentiation of rituximab’s
clinical efficacy.72,73
It is not surprising that several recent studies suggested
that CD20 is at least partially regulated by epigenetic
mechanisms. Tomita et al. demonstrated that treating a
CD20-negative B-cell line with the histone deacetylase
(HDAC) inhibitor trichostatin A resulted in robust upreg-
ulation of CD20 mRNA and protein.74 In vitro treatment of
primary cells obtained from relapsed CD20-negative B-
NHL patients using the DNA methyl-transferase (DNMT)
inhibitor 5-aza-2-deoxycytidine also led to the stimula-
tion of MS4A1 mRNA and cell-surface expression within
3 days, and restoration of rituximab sensitivity.75 Despite
the fact that CD20 stimulation by DNMT inhibitors was
described both in vitro75,76 and in vivo in patients with B-cell
malignancies,77 CD20 is less likely to be regulated by CpG
(de)methylation as its promoter region does not contain
any CpG islands up to ~5 kb upstream from the transcrip-
tion start site.76 However, it is plausible that DNMT inhi-
bition regulates the methylation status of transcription
factors critical for MS4A1 transcription, or some more
distant genomic regions (enhancers) are involved in
MS4A1 transcription. Furthermore, it was reported that a
Sin3A-HDAC1 co-repressor complex is recruited to the
MSA41 promoter in CD20-negative B-cell lines (Figure 2,
Table 1).76 This complex dissociates from the promoter
with 5-aza-2-deoxycytidine and trichostatin A treatment,
resulting in histone acetylation and partial restoration of
CD20 expression. Shimizu et al. showed that HDAC
inhibitors (valproic acid or romidepsin) are able to induce
CD20 expression in B-cell lines through MS4A1 promoter
hyperacetylation and recruit the SP1 transcription factor
within 48 hours (Figures 2 and 3, Table 1).65 At the
moment, several ongoing clinical trials are evaluating the
efficacy of epigenetic modulators in combination with rit-
uximab (Table 2). In the VALFRID study, pretreatment
with valproic acid before first-line therapy with CHOP
plus rituximab in DLBCL patients resulted in histone
acetylation, CD20 upregulation at the mRNA and cell-
surface levels78 and improved overall survival.79 In con-
trast, the analysis of three CLL patients from the PREVAIL
study showed no CD20 induction upon pretreatment
with valproic acid.80 A plausible explanation might be that
valproic acid induces a bivalent MS4A1 promoter status
in primary CLL cells in vivo as it induces histone acetyla-
tion, but also transient recruitment of the transcriptional
repressor EZH2 to the MS4A1 promoter (Figure 2, Table
1). Administering a DNMT inhibitor and pan-HDAC
inhibitor (valproic acid, romidepsin, trichostatin A,
SAHA) stimulates CD20 expression and might improve
anti-CD20 therapy in vivo, at least in some patients with
B-NHL. However, the clinical use of pan-HDAC
inhibitors is hindered by adverse effects77,79 and thus the
involvement of individual HDAC molecules and selective
HDAC inhibitors are undergoing pre-clinical studies.
Recently, entinostat, a selective HDAC1/4 inhibitor, was
G. Pavlasova and M. Mraz
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Table 2. List of novel drugs combined with anti-CD20 monoclonal antibodies in B-cell malignancies.
Drugs                               Pre-clinical studies                       Phase I: trial ID*  Phase II: trial ID*       Phase III: trial ID*       FDA approvals and comments
                                                                                              and status             and status                  and status                    
       Ibrutinib                          ↓CD20 in CLL cells in vitro                                                  NCT02007044                 NCT02264574                    FDA approved (2019) ibrutinib plus
                                                 and in vivo44,100                                                                                                                             (active)12                         (completed)49                              obinutuzumab for treatment-naïve
                                                                                                                                                                                                 NCT02165397                   CLL. No benefit from combination
                                                                                                                                                                                                 (active)118                           of ibrutinib and rituximab in CLL 
                                                                                                                                                                                                                                             (NCT02007044).12 FDA approved 
                                                                                                                                                                                                                                             (2018) ibrutinib in combination with
                                                                                                                                                                                                                                             rituximab for Waldenström’s
                                                                                                                                                                                                                                             macroglobulinemia. 
       Idelalisib                         Unknown                                                                                                                              NCT01539512                   FDA approved (2014) idelalisib in 
                                                                                                                                                                                                 (completed)110                             combination with rituximab for 
                                                                                                                                                                                                 NCT01659021                   relapsed CLL. 
                                                                                                                                                                                                 (terminated)111
       Duvelisib                         Unknown                                                                                    NCT02391545                 NCT02204982                    -
                                                                                                                                                       (terminated)                 (terminated)                   
       Acalabrutinib                  BTK inhibition ↓CD20 in CLL                                                                                          NCT02475681                   -
                                                 cells in vitro and in vivo44,100                                                                                                                                                        (active)109
       
       Venetoclax                      Unknown                                               NCT02296918                                                   NCT02950051                   FDA approved (2018) venetoclax in 
                                                                                                                  (active)119                                      (active)                              combination with rituximab for 
                                                                                                                                                                                                 NCT02005471                   CLL/SLL patients, with or without 
                                                                                                                                                                                                 (active)10                                              17p deletion, who have received at 
                                                                                                                                                                                                 NCT02242942                   least one prior therapy. FDA 
                                                                                                                                                                                                 (active)116                                            approved (2019) venetoclax in 
                                                                                                                                                                                                                                             combination with obinutuzumab for 
                                                                                                                                                                                                                                             previously untreated CLL/SLL. 
       Valproic acid                  ↑CD20 in B-cell lines in vitro65        NCT01622439 
                                                 and in DLBCL patients in vivo78            (completed)79
                                                                                                                                                                                             NCT02144623 
                                                                                                                  (completed)80
       5-Azacitidine,                  ↑CD20 in vitro75,76 and in vivo77        NCT01004991 
       5-aza-2-deoxycytidine                                                                   (completed)
                                                                                                                  NCT00901069 
                                                                                                                  (completed)
       Trichostatin A                 ↑CD20 in B-cell lines in vitro74
       Romidepsin                    ↑CD20 in B-cell lines in vitro65
       Entinostat                       ↑CD20 in B-cell lines in vitro81
     Bryostatin-1                    ↑CD20 in B-cell lines in vitro64                                                                                       NCT00087425 
                                                                                                                                                                                                                                                                                               (completed)
       Gemcitabine                  ↑CD20 in B-cell lines in vitro66                                                                                       NCT00169195 
                                                                                                                                                                                                                                                                                               (completed)120
                                                                                                                                                                                                 NCT02750670 
                                                                                                                                                                                                 (active)                              
       CpG                                  ↑CD20 in CLL cells in vitro121                                                                                                                                                     NCT00251394 
       oligodeoxynucleotides                                                                                                                                                (completed)122
       Aurora kinase A/B         ↑CD20 in immunotherapy-               NCT01397825 
       inhibitor (alisertib)     resistant  cell lines in vitro123                   (completed)72
                                                                                                                                                                                             NCT01695941 
                                                                                                                  (active)
       Farnesyltransferase    ↑CD20 in B-cell lines in vitro62
       inhibitor (L-744, 832)   
       TGFβ inhibitor              inhibits the suppression of CD20
       (LY364947)                     mediated by TGFβ in vitro99
       FOXO1 inhibitors          ↑CD20 expression in vitro and
       (AS1842856)                   in vivo70
↑: induction of expression; ↓: repression of expression; -: no decision; *: ID on clinicaltrials.gov.; ID: identity; FDA: Food and Drug Administration; CLL: chronic lymphocytic leukemia; BCR:

































reported to upregulate CD20 and improve rituximab effi-
cacy both in vitro and in a mouse model (Figure 2, Table
1).81 Additionally, Bobrowicz et al. identified HDAC6 as a
novel repressor of CD20 expression in B-cell lines and pri-
mary CLL cells (Figure 2, Table 1).82 HDAC6 was shown
to be overexpressed in CLL cells and its inhibition aug-
mented the efficacy of anti-CD20 monoclonal antibodies
in vitro and improved survival of complement-, NK cell-
and macrophage-competent mice (SCID Fox Chase mice)
injected with Raji cells and treated with rituximab.82
However, it seems that HDAC6 inhibitor does not induce
MS4A1 transcription, but only increases MS4A1 mRNA
translation. Its potential clinical use is, therefore, likely
limited to malignancies that have highly active MS4A1
transcription but escape anti-CD20 antibodies by pre-
venting its translation. This is not likely in most CLL
cases, although, one report has suggested that MS4A1
mRNA might be repressed post-transcriptionally by
microRNAs in CLL.83
Regulation of CD20 levels on the cell-surface during
therapy 
Besides transcriptional and epigenetic regulation, sever-
al studies have demonstrated CD20 downmodulation on
the B-cell surface in response to anti-CD20 therapy
(Figure 1). One of these mechanisms is called “shaving”.
Monocytes and macrophages recognize rituximab bind-
ing to CD20 and remove this complex from the B-cell sur-
face via the FcgRI-dependent process of endocytosis
called trogocytosis53 and this was observed in CLL
patients treated with rituximab in vivo (Figure 1).53,84,85
Alternatively, the acute change in CD20 levels in the
malignant B-cell population after rituximab infusion
might be partially due to elimination of those cells with
the highest CD20 levels. Indeed, we have shown that
after rituximab infusion in vivo, the antibody primarily
targets and eliminates a subpopulation of CLL cells with
the highest levels of CD20 via CDC, whereas many CLL
cells with pre-therapy low CD20 levels survive.34
Importantly, the CLL cells with the highest cell-surface
CD20 levels are also those with the highest BCR signaling
propensity and also represent the vast majority of Ki67-
positive cells in peripheral blood.34 This “targeting” of the
most aggressive intraclonal CLL cell subpopulation at
least partially explains the good clinical efficacy of ritux-
imab. It remains to be determined whether rituximab is
also targeting specific intraclonal cell subpopulations in
diseases such as follicular lymphoma and DLBCL, in
which malignant cells have relatively homogenously
higher CD20 cell-surface levels.
Another mechanism reducing CD20 expression on B
cells in response to anti-CD20 therapy is known as anti-
genic modulation (Figure 1).86 This refers to the active
internalization and subsequent degradation of
CD20/monoclonal antibody complexes demanding ener-
gy and cytoskeleton remodeling. Importantly, only type I
anti-CD20 monoclonal antibodies induce marked anti-
genic modulation. These anti-CD20 monoclonal antibod-
ies (e.g. rituximab and ofatumumab) recognize and bind
CD20 epitope in a different orientation than type II anti-
bodies (obinutuzumab) and are able to redistribute CD20
into lipid rafts on the plasma membrane.87,88 Type I anti-
CD20 monoclonal antibodies also have an approximately
two-fold higher capacity to bind CD20 epitope, which
makes them prone to internalization and proteolytic
degradation.86,89 Moreover, the extent of antigenic modu-
lation depends on the type of B-cell malignancy. The
most rapid internalization can be seen in CLL cells, fol-
lowed by mantle cell lymphoma cells, while follicular
lymphoma and DLBCL cells show relatively lower rates
of antigen internalization.86 Lim et al. suggested that dif-
ferent rates of internalization in B-cell malignancies are
due to different levels of inhibitory FcgRIIb on B cells
(predominantly expressed on CLL and mantle cell lym-
phoma cells).90 Rituximab was proposed to crosslink
CD20 and FcgRIIb on the same B cell, resulting in FcgRIIb
phosphorylation, and internalization of these complexes
into lysosomes for their degradation. 
The selection pressure caused by rituximab therapy can
also lead to the emergence of malignant B-cell clones that
are relatively or fully negative for cell-surface CD20
expression (Figure 1). In some DLBCL patients, mutations
in the MS4A1 coding sequence were identified; however,
mutations involving rituximab epitope are extremely
rare.91 Terui et al. analyzed CD20 mutations in samples
obtained from patients with previously untreated or
relapsed/refractory B-NHL and found MS4A1 mutations
in 11 out of 50 patients (22%).92 Importantly, in four cases
(8%), such mutations resulted in a C-terminal truncated
form of CD20 protein and reduced its cell-surface expres-
sion. Nakamaki et al. also reported a case of a relapsed
DLBCL patient with a homozygous MS4A1 gene deletion
after rituximab-based therapy.93
Notably, some recurrent genetic mutations in patients
with B-cell malignancies might affect CD20 levels, and be
favored during therapy. In a clinical trial comparing flu-
darabine and cyclophosphamide treatment with fludara-
bine, cyclophosphamide and rituximab treatment, it was
found that NOTCH1 mutations are associated with a rel-
ative resistance to the anti-CD20 therapy.94 Pozzo et al.
showed that NOTCH1-mutated CLL cells are character-
ized by a lower CD20 expression in comparison to that of
NOTCH1-wildtype CLL cells.95 Mutations in NOTCH1
intracellular domain (NICD) result in dysregulation of
HDAC-mediated epigenetic repression of CD20 through
interactions with the RBPJ transcription factor. RBPJ acts
as a negative regulator when forming a complex with
HDAC1/2; however, accumulation of mutated NOTCH1
in the nucleus results in the preferential formation of
NICD-RBPJ activating complex and higher HDAC1/2 lev-
els available for interactions with an MS4A1 promoter.
Recently, microenvironmental interactions in various B-
cell malignancies were brought into focus as these pro-
vide essential pro-proliferative and pro-survival signals
and promote drug resistance (reviewed by Seda &
Mraz48). Interactions between mesenchymal stromal cells
and CLL cells were shown to protect the leukemic cells
from rituximab-induced CDC96 and direct apoptosis,97
and this can be therapeutically targeted by integrin inhi-
bition (Figure 1).97 These observations led to the coining
of the term “cell adhesion-mediated antibody resistance”
as an analogy to the long-known “cell adhesion-mediated
drug resistance”, which refers to resistance to classical
chemotherapy. CD20 down-modulation in response to
microenvironmental stimuli might be a theoretical expla-
nation for cell adhesion-mediated antibody resistance.
This is supported by the observation that stimulating nor-
mal B cells by co-culture with CD40L-expressing fibrob-
lasts results in rapid CD20 endocytosis and thus reduces
the cell-surface levels of CD20.98 Additionally, Kawabata
CD20: functions and regulation
haematologica | 2020; 105(6) 1501
et al. observed in the Ramos cell line that TGFβ signaling
led to SMAD2/3 binding directly to the MS4A1 transcrip-
tion start site, resulting in CD20 repression.99 However,
we and others have shown that in CLL, the chemokine
CXCL12 (also known as SDF1) produced by stromal cells
in immune niches induces CD20 expression, and that the
intraclonal CLL cell subpopulation that recently exited
the lymph nodes is characterized by high levels of
CD20.34 This has an important consequence for the mech-
anism of rituximab’s action since, in vivo, rituximab infu-
sion leads to rapid and preferential elimination of this
aggressive, proliferative CLL cell subpopulation. The
remaining large proportion of CLL cells can survive the
rituximab therapy because of relatively weak cell-surface
levels of CD20, but these cells have a gene-expression
profile of non-activated CLL cells, which are relatively
less able to activate the BCR pathway, and do not prolif-
erate. It remains unclear which molecular pathways pro-
vide CLL cells in the lymph node microenvironment with
resistance to rituximab, despite having high levels of
CD20.97 The resistance to rituximab in the microenviron-
ment seems to be limited to rituximab-mediated apopto-
sis and CDC. 
Combinatorial therapy of novel drugs and anti-CD20
monoclonal antibodies 
For over a decade, scientists and clinicians have become
accustomed to the empirical experience that adding ritux-
imab to other therapies leads to increased therapeutic
efficacy in B-cell malignancies. This also prompted stud-
ies for strategies to induce higher CD20 levels on the B-
cell surface to potentially sensitize malignant cells to anti-
CD20 monoclonal antibodies (summarized in Table 2).
Several of these “CD20 inducers” are being explored in
preclinical or phase I/II clinical trials, including aurora
kinase inhibitors, FOXO1 inhibitors, and chromatin mod-
ulators. For example, it has been shown that in lym-
phomas, the aurora kinase inhibitor alisertib can be safely
and successfully used in combination with vincristine and
rituximab (phase I/II trial).72 Nevertheless, none of the
“CD20 inducers” has been prioritized for phase III trials
yet (see Table 2). Combining the BTK inhibitor ibrutinib
with rituximab was expected to increase the BTK
inhibitor’s clinical efficacy. This hypothesis was support-
ed by the observation that CLL/lymphoma cells become
more sensitive to apoptosis and anti-CD20 monoclonal
antibodies when mobilized from immune niches (a typi-
cal effect of BCR inhibitors).96,97 However, results from a
phase II study12 demonstrated no benefit from adding rit-
uximab to ibrutinib. Recent studies have shown that
CD20 levels are repressed during ibrutinib therapy and
that ibrutinib affects cells responsible for effector mecha-
nisms such as T/NK cells and macrophages. The reduc-
tion of CD20 levels by ibrutinib has a clear impact on rit-
uximab-mediated CDC and apoptosis. However, CD20 is
not completely lost, which still allows for anti-CD20
monoclonal antibodies to bind to cells. Skarzynski et al.100
also suggested that ibrutinib reduces complement
inhibitor CD55 levels, which might partially counterbal-
ance the effects of lower CD20, but it seems that in the
sum of all effects, rituximab or ofatumumab efficacy
decreases during ibrutinib therapy. 
CD20 levels appear to play an essential role in CDC
induced by rituximab, but they seem to be less relevant
for ADCC.101 Unfortunately, ibrutinib also affects the
functions of T cells and NK cells by inhibiting their BTK
or a related ITK. BTK is critical for regulating the func-
tions of NK cells as BTK-less NK cells have impaired cyto-
toxic activity.102 ITK signals downstream of the T-cell
receptor and is required to activate NK cells through
FcgRIII.103 Inhibiting BTK or ITK impairs the cytotoxic
functions of NK cells (degranulation, cytokine secretion)
and ADCC mediated by type I and II anti-CD20 mono-
clonal antibodies.104,105 Thus ibrutinib may impair T- and
NK-cell functions through either BTK or ITK, or both.104 It
has also been suggested that phagocytosis by
macrophages is affected by ibrutinib, but it is unclear if
this is due to BTK inhibition in these cells or an off-target
effect.104-106 Based on the results from the iLLUMINATE
study,49 the Food and Drug Administration has already
approved the combination of ibrutinib plus obinutuzum-
ab for treatment-naïve patients with CLL (Table 2).
However, the control arm of the study with chlorambucil
plus obinutuzumab did not allow a conclusion on
whether obinutuzumab provided a real benefit.
Alternatively, sequential ibrutinib administration after the
anti-CD20 monoclonal antibody could conceivably allow
for better antibody effects. However, a clinical trial in
CLL showed that sequential treatment with ofatumumab
before ibrutinib was inferior to starting ibrutinib first, fol-
lowed by the administration of ibrutinib and ofatumum-
ab.107 Since obinutuzumab acts in part through mecha-
nisms different from those of type I antibodies (ritux-
imab, ofatumumab), its combination with ibrutinib may
lead to different effects and increased clinical efficacy.
Alternatively, other BTK inhibitors, such as acalabrutinib,
are more selective with less off-target activity and likely
do not interfere with antibody-dependent cellular phago-
cytosis or ADCC.108 It needs to be determined whether
acalabrutinib is more suitable than ibrutinib for therapeu-
tic combination with anti-CD20 monoclonal antibodies.
Recently, a phase III study showed that acalabrutinib
combined with obinutuzumab is highly efficient in pro-
longing progression-free survival when compared to
obinutuzumab and chlorambucil in patients with previ-
ously untreated CLL.109 
An interesting case is also the PI3Kd inhibitor idelalisib,
which is currently approved for use in combination with
rituximab to treat relapsed CLL based on a comparison to
rituximab alone (Table 2).110 A similar phase III study
showed that the progression-free survival of participants
treated with a combination of idelalisib and ofatumumab
was significantly longer than that of the group treated
with ofatumumab only (Table 2).111 However, it is unclear
whether adding rituximab or ofatumumab to idelalisib
actually provides any clinical benefit, and based on the
understanding of CD20 regulation, it is very likely that
PI3K inhibitors also repress CD20 expression. In fact, data
indicate that any inhibitor repressing Akt or NFκB or
CXCR4 activity in B cells, such as a SYK inhibitor, BTK
inhibitor, PI3Kd inhibitor, or CXCR4 antagonist, also
reduces CD20 expression, leading to decreased binding of
anti-CD20 monoclonal antibodies.44,70,100,112,113 Notably,
SRC inhibitors such as dasatinib also repress CD20 tran-
scription and impair NK cell functions.112 Additionally,
PI3Kd plays a critical role in maturation, development,
and effector functions of NK cells, which would indicate
that it might impair ADCC. However, some studies indi-
cate that this might be less prominent than ibrutinib’s
effects114 or that idelalisib does not reduce ADCC at all.115
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Idelalisib was also shown to decrease IFNg production by
NK cells, and reduce secretion of various cytokines by T
cells (IL6, IL10, TNFα, and CD40L).115 More studies will
be needed to determine whether other BTK or PI3K
inhibitors have a better profile in terms of affecting
ADCC/antibody-dependent cellular phagocytosis, but it
seems inevitable that they will all lead to reduced levels
of CD20.
The BH3-mimetic venetoclax was also tested in combi-
nation with anti-CD20 monoclonal antibodies. It seems
that in contrast to “BCR inhibitors”, there are no obvious
biological reasons preventing an additive or synergistic
effect of such a combination. The Food and Drug
Administration granted approval for the use of venetoclax
in combination with obinutuzumab for patients with pre-
viously untreated CLL/small lymphocytic lymphoma and
in combination with rituximab to treat patients with
CLL/ small lymphocytic lymphoma who have received at
least one prior therapy (Table 2).116 The biological ration-
ale for such combinations in CLL is provided, among oth-
ers, by a study showing that combining venetoclax and
anti-CD20 monoclonal antibodies overcomes microenvi-
ronment-mediated resistance of CLL cells to venetoclax
monotherapy in vitro.117
Conclusion
Although CD20 is considered to be an ideal therapeutic
target and rituximab-based immunotherapy has become
a standard of care for a majority of B-cell malignancies, it
is still unclear what all the functions of CD20 are, and
how its expression is regulated. The main reason is the
large heterogeneity of patients with B-cell malignancies
and the lack of mouse models with an evident phenotype
which makes CD20 analysis in vivo more difficult. A full
understanding of the complexity of regulation of CD20,
its physiological function and the exact mechanism of
action of anti-CD20 monoclonal antibodies is of pivotal
importance to develop new modified anti-CD20 mono-
clonal antibodies and their therapeutic combination that
would yield better clinical efficacy and/or less toxicity.
Recently, the possible role of CD20 in microenvironmen-
tal interactions was underscored by the observation that
CD20 is upregulated in the context of immune niches.
This is likely to be of physiological importance, especially
for BCR signaling; however, it is unclear if this is related
to the putative function of CD20 as a regulator of calcium
flux triggered by BCR or any potential role in T-cell inter-
actions or some additional function(s). Further investiga-
tion of the physiological function of CD20 is required,
including the identification of molecules that interact
with CD20, since this has implications for the develop-
ment of rational therapeutic combinations and strategies.
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